Immitra Bio
Builds a scalable in-vivo genetic medicine platform aimed at developing therapies delivered directly inside the body.
Overview
Immitra Bio is developing a scalable in-vivo genetic medicine platform, focused on enabling genetic therapies that act within the body rather than through ex-vivo processes. The company sits in the genetic medicine market, where platform scalability is a central differentiator. The Zürich-based company raised $3 million in a pre-seed round announced in July 2026, reported as €2.58 million, to scale its platform. Although categorized as AI in the source data, the disclosed business is genetic medicine rather than an AI product.
Funding History
Zürich-based Immitra Bio secures €2.58 million to scale its scalable in-vivo genetic medicine platform
Frequently Asked Questions
- How much has Immitra Bio raised in total?
- Immitra Bio has raised a total of $3M across 1 funding round.
- Who are Immitra Bio's investors?
- Immitra Bio's investors include Backbone Ventures.
- What does Immitra Bio do?
- Immitra Bio is developing a scalable in-vivo genetic medicine platform, focused on enabling genetic therapies that act within the body rather than through ex-vivo processes. The company sits in the genetic medicine market, where platform scalability is a central differentiator. The Zürich-based company raised $3 million in a pre-seed round announced in July 2026, reported as €2.58 million, to scale its platform. Although categorized as AI in the source data, the disclosed business is genetic medicine rather than an AI product.
- Where is Immitra Bio headquartered?
- Immitra Bio is headquartered in Zürich, Switzerland.
Investors
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.